|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM27414008X |
| 003 |
DE-627 |
| 005 |
20250222005419.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2017 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2017.07.005
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0913.xml
|
| 035 |
|
|
|a (DE-627)NLM27414008X
|
| 035 |
|
|
|a (NLM)28739191
|
| 035 |
|
|
|a (PII)S1521-6616(17)30342-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ogura, Mineko
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice
|
| 264 |
|
1 |
|c 2017
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 13.12.2017
|
| 500 |
|
|
|a Date Revised 10.12.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2017 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Oral administration of biologics may be a feasible approach for immune therapy that improves drug safety and potentiates mechanisms of tolerance at mucosal barriers. We tested the ability of a fully human non-FcR binding anti-CD3 mAb, foralumab, to prevent skin xenograft rejection in mice with human immune systems. At an intragastric dose of 15μg, the drug could transit through the small bowel. Serum absorption and binding of lymphoid cells was seen and proliferative responses of splenic CD8+ T cells to mitogen were reduced. Five consecutive daily doses, then weekly dosing led to indefinite graft acceptance without depletion of peripheral T cells. Proliferative and cytokine responses to activation of splenocytes with PHA were reduced. The serum levels of IL-10 but not TNF were increased 6days after application of the skin graft. Oral treatment with anti-CD3 mAb may represent a feasible approach for immune modulation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Anti-CD3
|
| 650 |
|
4 |
|a Immune tolerance
|
| 650 |
|
4 |
|a Monoclonal antibody
|
| 650 |
|
4 |
|a Oral biologic
|
| 650 |
|
7 |
|a Antibodies, Monoclonal
|2 NLM
|
| 650 |
|
7 |
|a CD3 Complex
|2 NLM
|
| 650 |
|
7 |
|a foralumab
|2 NLM
|
| 650 |
|
7 |
|a J43DL56H6M
|2 NLM
|
| 700 |
1 |
|
|a Deng, Songyan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Preston-Hurlburt, Paula
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ogura, Hideki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shailubhai, Kunwar
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kuhn, Chantal
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Weiner, Howard L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Herold, Kevan C
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 183(2017) vom: 07. Okt., Seite 240-246
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:183
|g year:2017
|g day:07
|g month:10
|g pages:240-246
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2017.07.005
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 183
|j 2017
|b 07
|c 10
|h 240-246
|